Metabolism, Excretion, and Pharmacokinetics of Selumetinib, an MEK1/2 inhibitor, in Healthy Adult Male Subjects.

A. Dymond,C. Howes,C. Pattison,Karen So,G. Mariani,M. Savage,S. Mair,G. Ford,Paul D. Martin
DOI: https://doi.org/10.1016/j.clinthera.2016.09.002
IF: 3.637
2016-11-01
Clinical Therapeutics
Abstract:
What problem does this paper attempt to address?